Ascendis Pharma Growth Disorders A/S: Financial statements 2021
CVR: 32323677
Source: annual report 2021, Danish Business Authority
01/01/2021 – 31/12/2021
Ascendis Pharma Growth Disorders A/S (CVR 32323677) has filed annual accounts for 2021. In 2021, the company reported a gross profit of EUR -47,933,482 and a net result of EUR -50,957,882 compared with EUR -32,098,569 the year before. Equity in the 2021 report amounted to EUR -140,441,787.
- Gross Profit
- EUR -47,933,482
- Profit/Loss
- EUR -50,957,882
- Equity
- EUR -140,441,787
- Total Assets
- EUR 9,546,001
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | - | -47.9M EUR | -51M EUR | -140.4M EUR | 0 |
| 2020 | - | -30.2M EUR | -32.1M EUR | -89.5M EUR | 0 |
| 2019 | - | -17.9M EUR | -19M EUR | -57.4M EUR | 0 |
| 2018 | - | -14.4M EUR | -15.3M EUR | -38.4M EUR | 0 |
| 2017 | - | -13.2M EUR | -13.7M EUR | -23M EUR | 0 |
Official annual report
Find more companies like Ascendis Pharma Growth Disorders A/S
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorEvents in 2021
Ascendis Pharma Growth Disorders A/S has published its annual report for 2020. Gross profit came to DKK -30,184,950, and the net result was DKK -32,098,569.
About Ascendis Pharma Growth Disorders A/S
Ascendis Pharma Growth Disorders A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ASCENDIS PHARMA, CIRCULATORY DISEASES DIVISION A/S and ASCENDIS PHARMA RELAXIN DIVISION A/S. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR -190,726,000 and a net result of EUR -225,725,000 compared with EUR -176,019,000 the year before. Equity in the 2025 report amounted to EUR -723,740,000.
